

Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure committee meeting 6

Date: 23/01/2024

Location: via Zoom

Minutes: Final

Committee members present:		
Abdallah Al-Mohammad		Present via Zoom
Gayle Campbell		Present via Zoom
Joseph Mills (Chair)		Present via Zoom
Richard Mindham		Present via Zoom
Susan Piper (Topic Advisor)		Present via Zoom
Chakravarthi Rajkumar		Present via Zoom until 12.30
Delyth Rucarean		Present via Zoom
Duwarakan Satchithananda		Present via Zoom
Louis Savage		Present via Zoom
Eduard Shantsila		Present via Zoom
Clare Taylor		Present via Zoom
Colin Wilkinson		Present via Zoom
Hugh Gallagher		Present via Zoom
Nigel Beckett		Present via Zoom

In attendance:		
Annette Chalker	Technical Analyst	Present via Zoom
Catrina Charlton	Guideline Commissioning Manager	Present via Zoom
Jemma Deane	Senior Information Specialist	Present via Zoom
Kirsty Luckham	Health Economist	Present via Zoom
Lisa Miles	Technical Analyst	Present via Zoom
Sade Naku	Health Economist	Present via Zoom
Eleanor Samarasekera	Senior Technical Analyst	Present via Zoom
Sharon Swain	Associate	Present via Zoom

	Director/Guideline Lead	
Daniel Davies	Project Manager	Present via Zoom
David Wonderling	Senior Health Economics Adviser	Present via Zoom

Observers:	
Emily Herrett	INTEGRATE study
Frederick Martineau	INTEGRATE study
Laurie Tomlinson	INTEGRATE study

Apologies:	

1. Welcome and objectives for the meeting
<p>The Chair welcomed the Committee members and attendees to the 6th meeting on the update of the pharmacological management of chronic heart failure.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the objectives of the meeting, which included an update on the health economic model and a review of the evidence for the effectiveness of mineralocorticoid receptor antagonists (eplerenone, finerenone, and spironolactone) in people with chronic heart failure with preserved ejection fraction</p>
2. Confirmation of matters under discussion, and declarations of interest
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were:</p> <ul style="list-style-type: none"> Review of the clinical and cost effectiveness of intravenous iron supplementation in adults with chronic heart failure and iron deficiency <p>The Chair and a senior member of the technical team reviewed the declarations of interest register for interests previously declared and noted that nobody was conflicted for this meeting.</p> <p>The Chair asked everyone to verbally declare any interests in addition to those previously declared, none were declared</p>

3 &4 Evidence Review: What is the clinical and cost effectiveness of mineralocorticoid receptor antagonists (eplerenone, finerenone, and spironolactone) in people with chronic heart failure with preserved ejection fraction?
<p>The Committee were presented with the evidence review and discussed the evidence.</p> <p>Draft recommendations were made.</p>
4. HE modelling update
The Committee were presented with an update on the health economic modelling work
5. Committee review of older recommendations
SS raised older recommendations for review with the committee
6. Any other business
None

Date of next meeting: Monday 24 February 2024, 1000-1600

Location of next meeting: Virtual via Zoom